761 related articles for article (PubMed ID: 27215744)
21. Visual acuity outcomes and anti-VEGF therapy intensity in macular oedema due to retinal vein occlusion: a real-world analysis of 15 613 patient eyes.
Ciulla T; Pollack JS; Williams DF
Br J Ophthalmol; 2021 Dec; 105(12):1696-1704. PubMed ID: 33055088
[TBL] [Abstract][Full Text] [Related]
22. Comparison of Aflibercept, Bevacizumab, and Ranibizumab for Treatment of Diabetic Macular Edema: Extrapolation of Data to Clinical Practice.
Heier JS; Bressler NM; Avery RL; Bakri SJ; Boyer DS; Brown DM; Dugel PU; Freund KB; Glassman AR; Kim JE; Martin DF; Pollack JS; Regillo CD; Rosenfeld PJ; Schachat AP; Wells JA;
JAMA Ophthalmol; 2016 Jan; 134(1):95-9. PubMed ID: 26512939
[TBL] [Abstract][Full Text] [Related]
23. Comparison of Outcomes and Costs of Ranibizumab and Aflibercept Treatment in Real-Life.
Schmid MK; Reich O; Faes L; Boehni SC; Bittner M; Howell JP; Thiel MA; Signorell A; Bachmann LM
PLoS One; 2015; 10(8):e0135050. PubMed ID: 26241852
[TBL] [Abstract][Full Text] [Related]
24. Association Between Hyperreflective Dots on Spectral-Domain Optical Coherence Tomography in Macular Edema and Response to Treatment.
Hwang HS; Chae JB; Kim JY; Kim DY
Invest Ophthalmol Vis Sci; 2017 Nov; 58(13):5958-5967. PubMed ID: 29183041
[TBL] [Abstract][Full Text] [Related]
25. Change in Diabetic Retinopathy Through 2 Years: Secondary Analysis of a Randomized Clinical Trial Comparing Aflibercept, Bevacizumab, and Ranibizumab.
Bressler SB; Liu D; Glassman AR; Blodi BA; Castellarin AA; Jampol LM; Kaufman PL; Melia M; Singh H; Wells JA;
JAMA Ophthalmol; 2017 Jun; 135(6):558-568. PubMed ID: 28448655
[TBL] [Abstract][Full Text] [Related]
26. Visual acuity outcomes and anti-VEGF therapy intensity in diabetic macular oedema: a real-world analysis of 28 658 patient eyes.
Ciulla TA; Pollack JS; Williams DF
Br J Ophthalmol; 2021 Feb; 105(2):216-221. PubMed ID: 32265201
[TBL] [Abstract][Full Text] [Related]
27. Persistent Macular Thickening After Ranibizumab Treatment for Diabetic Macular Edema With Vision Impairment.
Bressler SB; Ayala AR; Bressler NM; Melia M; Qin H; Ferris FL; Flaxel CJ; Friedman SM; Glassman AR; Jampol LM; Rauser ME;
JAMA Ophthalmol; 2016 Mar; 134(3):278-85. PubMed ID: 26746868
[TBL] [Abstract][Full Text] [Related]
28. Pharmacokinetics of ranibizumab after intravitreal administration in patients with retinal vein occlusion or diabetic macular edema.
Zhang Y; Yao Z; Kaila N; Kuebler P; Visich J; Maia M; Tuomi L; Ehrlich JS; Rubio RG; Campochiaro PA
Ophthalmology; 2014 Nov; 121(11):2237-46. PubMed ID: 25001159
[TBL] [Abstract][Full Text] [Related]
29. Scheduled versus Pro Re Nata Dosing in the VIEW Trials.
Richard G; Monés J; Wolf S; Korobelnik JF; Guymer R; Goldstein M; Norenberg C; Sandbrink R; Zeitz O
Ophthalmology; 2015 Dec; 122(12):2497-503. PubMed ID: 26477840
[TBL] [Abstract][Full Text] [Related]
30. CHANGES IN PLASMA VASCULAR ENDOTHELIAL GROWTH FACTOR LEVEL AFTER INTRAVITREAL INJECTION OF BEVACIZUMAB, AFLIBERCEPT, OR RANIBIZUMAB FOR DIABETIC MACULAR EDEMA.
Hirano T; Toriyama Y; Iesato Y; Imai A; Murata T
Retina; 2018 Sep; 38(9):1801-1808. PubMed ID: 29280940
[TBL] [Abstract][Full Text] [Related]
31. Switching from pro re nata to treat-and-extend regimen improves visual acuity in patients with neovascular age-related macular degeneration.
Kvannli L; Krohn J
Acta Ophthalmol; 2017 Nov; 95(7):678-682. PubMed ID: 28139082
[TBL] [Abstract][Full Text] [Related]
32. Intravitreal Aflibercept Injection in Diabetic Macular Edema Patients with and without Prior Anti-Vascular Endothelial Growth Factor Treatment: Outcomes from the Phase 3 Program.
Do DV; Nguyen QD; Vitti R; Berliner AJ; Gibson A; Saroj N; Soo Y; Boyer DS
Ophthalmology; 2016 Apr; 123(4):850-7. PubMed ID: 26832658
[TBL] [Abstract][Full Text] [Related]
33. Treat-and-extend therapy using intravitreal aflibercept for neovascular age-related macular degeneration: 2-year real-world practice data from Slovenia.
Jaki Mekjavić P; Gregorčič B; Oberč C; Podgoršek S
BMC Ophthalmol; 2018 Dec; 18(1):333. PubMed ID: 30572850
[TBL] [Abstract][Full Text] [Related]
34. Demographics of patients receiving Intravitreal anti-VEGF treatment in real-world practice: healthcare research data versus randomized controlled trials.
Ziemssen F; Feltgen N; Holz FG; Guthoff R; Ringwald A; Bertelmann T; Wiedon A; Korb C;
BMC Ophthalmol; 2017 Jan; 17(1):7. PubMed ID: 28103831
[TBL] [Abstract][Full Text] [Related]
35. Time to clinically significant visual acuity gains after ranibizumab treatment for retinal vein occlusion: BRAVO and CRUISE trials.
Thach AB; Yau L; Hoang C; Tuomi L
Ophthalmology; 2014 May; 121(5):1059-66. PubMed ID: 24424249
[TBL] [Abstract][Full Text] [Related]
36. Assessment of intravitreal anti-VEGF drugs and dexamethasone for retinal diseases in real world setting: A multi-centre prospective study from Southern Italy.
Scondotto G; Sultana J; Vadalà M; Avitabile T; Cillino S; Foti SS; Labbate L; Longo A; Mirabelli E; Puzo MR; Rapisarda C; Ibanez Toro P; Trombetta CJ; Trifirò G; Virgili G;
Eur J Ophthalmol; 2022 Sep; 32(5):3064-3073. PubMed ID: 35075918
[TBL] [Abstract][Full Text] [Related]
37. Real-world evidence of safety profile of intravitreal bevacizumab (Avastin) in an Indian scenario.
Jain P; Sheth J; Anantharaman G; Gopalakrishnan M
Indian J Ophthalmol; 2017 Jul; 65(7):596-602. PubMed ID: 28724817
[TBL] [Abstract][Full Text] [Related]
38. Short-time effect of intravitreal injections on retinal vascular oxygenation and vessel diameter in patients with diabetic macular oedema or neovascular age-related macular degeneration.
Mitsch C; Pemp B; Pollreisz A; Gleiss A; Karst S; Scholda C; Sacu S; Schmidt-Erfurth U
Acta Ophthalmol; 2020 May; 98(3):e301-e308. PubMed ID: 31654481
[TBL] [Abstract][Full Text] [Related]
39. Comparison of photodynamic therapy, ranibizumab/bevacizumab or combination in the treatment of myopic choroidal neovascularisation: a 9-year-study from a single centre.
Rishi P; Rishi E; Bhende M; Agarwal V; Vyas CH; Valiveti M; Bhende P; Rao C; Susvar P; Sen P; Raman R; Khetan V; Murali V; Ratra D; Sharma T
Br J Ophthalmol; 2016 Oct; 100(10):1337-40. PubMed ID: 26792945
[TBL] [Abstract][Full Text] [Related]
40. Vascular endothelial growth factor inhibitor use and treatment approach for choroidal neovascularization secondary to pathologic myopia.
Pakzad-Vaezi K; Mehta H; Mammo Z; Tufail A
Expert Opin Biol Ther; 2016 Jul; 16(7):873-81. PubMed ID: 26985834
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
